Cancer diagnostics firm Precipio's Q2 revenue rises, adjusted EBITDA turns positive - PRPO News | RalliesCancer diagnostics firm Precipio's Q2 revenue rises, adjusted EBITDA turns positive
P
PRPO• Outlook
- Company says it is well positioned to continue building on recent momentum
Overview
- US specialty cancer diagnostics firm's Q2 revenue rose 22% yr/yr to $7.0 mln
- Adjusted EBITDA improved to $0.4 mln, driven by higher revenue and lower stock-based compensation
- Company ended Q2 with cash exceeding $3 mln, up from $1.1 mln a year earlier
Key details
| Metric | Actual | Consensus Estimate |
|---|
| Q2 Revenue | $7 mln | |
Result drivers
- Customer growth - Co said customer growth contributed to quarterly revenue surpassing $7 mln for the first time
- Product revenue increase - Product revenues increased 21% from previous high of $750K in Q4-2025
- Lower stock-based compensation - Adjusted EBITDA improvement driven in part by decrease in stock-based compensation expense
MDWK
•
